2026· Journal of emerging investigators· 0 citations· 37 references
TL;DR
The sequence and structural similarity between Drosophila and human proteins was examined to address the question of whether Drosophila proteins can be used as human surrogates for early drug discovery, and it was hypothesized that the sequence identity within the drug binding pocket of D. melanogaster proteins would exceed 50% when compared to their human homologs.
Abstract
Drug discovery is a complex process involving various methods used to identify biological or chemical entities that can modify the function of specific proteins believed to play a role in disease. Drosophila melanogaster, or fruit fly, has been used by researchers for over a century to study human biology, genetics of human disease, and to find new medicines. Proteins from non-human species are utilized in the early stages of drug discovery when they share high sequence similarity with human homologs and are more accessible than human proteins. This study examined the sequence and structural similarity between Drosophila and human proteins to address the question of whether Drosophila proteins can be used as human surrogates for early drug discovery. We hypothesized that the sequence identity within the drug binding pocket of D. melanogaster proteins would exceed 50% when compared to their human homologs. To assess this hypothesis, we compared five protein sequences and crystal structures from D. melanogaster complexed with approved drugs or potential drug candidates to their human homologs. The overall sequence identity between the 2 species ranged from 38 to 71%, with good structural overlap. In the drug binding pocket, the sequence identity was 55 to 100%, supporting the hypothesis. However, we also identified cases where amino acids were not conserved in functionally critical regions, limiting the use of certain Drosophila proteins for identifying human therapeutic agents. The approach described here sheds light on the diverse aspects that must be considered when selecting proteins to address drug discovery questions.
A modular mass spectrometry-based assay for the analysis of orthologous proteins across species in the context of translational science using ataxin-2 (ATXN2) as an example provides a translational blueprint that can be adapted to other orthologues, reducing cost and timeline in drug development.
Blandine Rougemont, Julie Borgel, Zoe Walker et al.· Journal of Proteome Research· 0 citations
Large-scale CRISPR base editing mutagenesis screens across 30 PI3K pathway proteins in three disease-relevant cancer cell models establish high-throughput base editing mutagenesis combined with structural analysis as a scalable strategy to delineate structure–function relationships and inform drug development.
Molecular docking emerged as an irreplaceable technique of structure-based drug design, revolutionizing the early stages of modern drug discovery since its introduction in the 1980s. Docking is widely used in the rational drug development to estimate binding affinity of newly designed compounds to active sites of selec...
J. Savić, M. Miličević, V. Dobričić et al.· Zbornik radova· 0 citations
Advances in veterinary medicine have prolonged the lifespan of companion animals. As a result, the burden of neoplastic diseases has increased. While targeted anticancer drugs are widely used in human oncology, their clinical translation to companion animals remains limited. Therefore, a systematic framework for priori...
Seoung-Woo Lee, Hee-Yeon Kim, Seong-Kyoon Choi et al.· Journal of Veterinary Medica...· 0 citations
Modern drug discovery relies on accurate computational methods for predicting drug-target interactions. When trained on hundreds of millions of protein sequences, transformer-based methods such as ProteinBERT demonstrate high accuracy in predicting protein function and structural properties, including disordered region...
D. Bock, S. Grozdanić, Vladimir Jacimovic et al.· 2026 IEEE 4th Conference on...· 0 citations
An integrated computational framework combining microarray-based gene expression profiling, network pharmacology, and structure-based drug discovery identifies EGFR as a potential therapeutic target in ADPKD and highlights Luteolin and Triptonolide as computationally prioritized phytochemical lead candidates for furthe...
I. U. Haq, Israr Hussain, A. Mohammad et al.· Computational biology and ch...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.